NKA Bio

When minutes count, our antibody buys hours.

Baltimore, United States · Founded 2024 · $1.3M raised

Founded
2024
Website
nkabio.com
Total Funding
$1.3M
Last Round
$30K SeedNov 2025
Rounds
4

About

NKA Bio is a biotech startup developing novel antibody therapeutics for critically ill trauma patients. Founded on research by the first Director of Emergency Medicine at Johns Hopkins, NKA Bio's lead candidate NKA01 is a monoclonal antibody designed to neutralize the body's shock response — pressing pause on death with a low-volume prefilled syringe injection by EMS at the point of injury to buy more time for transport and life-saving surgery. The company operates R&D facilities in Baltimore, Maryland equipped for antibody engineering and assay development, with a lead candidate on a path to enter the clinic.

Summary

NKA Bio is a Healthcare company based in Baltimore, United States, founded in 2024. It has raised $1.3M in total across 4 rounds, most recently a $30K Seed round in Nov 2025. Investors include Techstars.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

GrantNov 2025
$1.3M

Sign up to see all 4 rounds

Seed through Grant — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

NKA Bio on Indexed.vc
<a href="https://indexed.vc/companies/nka-bio"><img src="https://indexed.vc/api/badge/company/nka-bio" alt="NKA Bio on Indexed.vc" width="260" height="76" /></a>